$ASPN

ASPEN AEROGELS INC (ASPN): Results of Operations and Financial Condition

ASPEN AEROGELS INC (ASPN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Aspen Aerogels, Inc. Reports Second Quarter 2026 Financial Results and Recent Business Highlights Q2 2026 Thermal Barrier revenue of $29.5 million, up 81% quarter-over-quarter Q3 2026 expected revenue range of $65 to $8

Original reporting
Published Aug 6, 2026, 10:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 10:35 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$ASPN
Neutral
medium confidence
Mentioned
$ASPN
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ASPNNeutralHigh
01

Why it matters

Traders can reprice the stock based on the combination of a weak YoY Q2 revenue and net loss, plus a materially improved Q3 adjusted EBITDA range, while monitoring execution risk from the East Providence incident and the Statesboro asset sale process.

02

Market read

Fresh Q3 guidance ranges and incident cost assumptions create a clear near-term catalyst for earnings-model updates and risk management.

03

What to watch

Insurance recovery is expected to be collected in Q3, but guidance explicitly excludes business interruption recoveries, leaving margin outcomes sensitive to claim timing and incident-related cost creep.

Relevance 7/10Novelty 9/10Timing: today’s SEC 8-K release with Q3 2026 guidance ranges

Background

This SEC 8-K (Item 2.02) includes Aspen’s Q2 2026 financial results and a press-release exhibit with operational updates and forward guidance.

Company-level read

Ticker impact

$ASPNNeutralMedium confidence
Context

Aspen reported Q2 2026 results and guided Q3 revenue $65M to $80M and adjusted EBITDA $7M to $15M, citing East Providence incident costs.

Expected impact

Near-term volatility likely around the Q3 outlook ranges and any market skepticism about insurance recovery timing and margin durability.

Evidence & confidence

The filing provides fresh, decision-relevant numbers (Q2 print plus explicit Q3 revenue, net loss, and adjusted EBITDA ranges) and ties them to a specific operational disruption with insurance claims not assumed in the guidance.

Market effects

EV thermal barrier demand and regulatory/incentive sensitivity are highlighted as a driver of segment revenue volatility.

East Providence, Rhode Island manufacturing disruption and restart execution are central to near-term supply and cost dynamics.

European Thermal Barrier momentum and OEM program ramp (including JLR architectures) support longer-cycle demand visibility.

Counterpoint

The raised European outlook and JLR PyroThin award may not offset North American regulatory uncertainty quickly enough to sustain the adjusted EBITDA ramp.

Key entities

  • Aspen Aerogels, Inc.

    Reports Q2 2026 results, provides Q3 2026 guidance, and discusses the East Providence incident and staged manufacturing restart.

  • Jaguar Land Rover

    Awarded Aspen’s PyroThin for two next-generation vehicle architectures with start of production expected in 2027.

  • East Providence incident (April 2026)

    Property damage and incident-related costs drive Q2 losses; company expects insurance receivable collection in Q3.

Related articles

$ASPNMed

Beerenberg Prevails in Patent Case Against Aspen Aerogels

South Korea’s Patent Court invalidated three Aspen Aerogels patents covering improved hydrophobic aerogel material, according to the company’s press release. The ruling upheld the Intellectual Property Trial and Appeal Board’s view that the patents failed patentability requirements. Beerenberg, an insulation-products firm, said the decision removes uncertainty over infringement claims.

$JANMedAI 8/10

JAN Q2 Earnings Call Highlights

Janus Living (NYSE:JAN) reported sequential same-store NOI margin down 40 bps, citing seasonality. Occupancy rose for independent living but fell for skilled nursing. The company acquired two communities for $105M, sold one for $23M, and completed $1B more acquisitions post-quarter. It raised 2026 FFO guidance to $0.95-$0.98 and same-store adjusted NOI growth to 13%-17%.

$JOBYMedAI 8/10

Joby Aviation Q2 Earnings Call Highlights

Joby Aviation (NYSE:JOBY) raised full-year revenue guidance to $115 million to $125 million from $105 million to $115 million. Q2 cash use was about $202 million and GAAP net loss was $245 million, including a $108 million non-cash warrant and earn-out fair value change. For 2H 2026, it expects $385 million to $415 million cash use. The company said aircraft availability is a key constraint on Blade routes and outlined manufacturing, infrastructure, and JV plans with Toyota.

$JHXMedAI 8/10

James Hardie Industries Q1 Earnings Call Highlights

James Hardie (NYSE:JHX) said about one-third of fiber-cement growth came from strategic initiatives, one-third from prior-year destocking comparisons, and the rest from price and mix. June sell-through rose 19%. Deck, Rail & Accessories sales fell 5% to $305.1M with 27.1% Adjusted EBITDA margin. Q2 net sales forecast $1.485B-$1.575B and FY2027 outlook raised; FCF Q1 was $254M and it redeemed $400M notes.

$IXMed

Orix Corp Ads Q1 Earnings Call Highlights

ORIX (NYSE: IX) discussed Q1 results and outlook on an earnings call, including potential Q3 Kioxia sale and valuation losses tied to Kioxia’s end-September share price. ORIX shifted its dividend basis to adjusted profits, targeting an interim dividend of JPY 107.27 per share and full-year JPY 187.36. It reported JPY 115.7B capital gains and about JPY 300B capital-recycling inflows, and continued a JPY 250B buyback.

$CPTMedAI 8/10

Camden Property Trust (CPT) Q2 2026 Earnings Call Transcript

Camden Property Trust (CPT) discussed its Q2 2026 earnings call, focusing on exiting its California multifamily portfolio. According to management, it sold the 19-year-old California portfolio for $1.625 billion, with trailing 12-month FFO and AFFO yields of 5.6% and 5.2%. Camden repurchased $694 million of shares and closed $645 million of acquisitions plus $195 million of awarded acquisitions, reaffirming $6.75/share FFO guidance.